Table 1.

Baseline characteristics of the intention-to-treat population.

CharacteristicsOnce-a-week group (N = 250)Once-every-3-weeks group (N = 260)
Sex
 Male180 (72.0%)177 (68.1%)
 Female70 (28.0%)83 (31.9%)
Median age, range (years)43 (21–65)44.5 (19–65)
Karnofsky scale
 90–100219 (87.6%)222 (85.4%)
 70–8031 (12.4%)38 (14.6%)
Histopathology
 WHO II4 (1.6%)4 (1.5%)
 WHO III246 (98.4%)256 (98.5%)
T classification
 T12 (0.8%)1 (0.4%)
 T29 (3.6%)8 (3.1%)
 T3210 (84.0%)213 (81.9%)
 T429 (11.6%)38 (14.6%)
N classification
 N029 (11.6%)35 (13.5%)
 N1112 (44.8%)112 (43.1%)
 N281 (32.4%)84 (32.3%)
 N328 (11.2%)29 (11.1%)
Staging
 III197 (78.8%)199 (76.5%)
 IVA25 (10.0%)32 (12.3%)
 IVB28 (11.2%)29 (11.2%)
Pretreatment Epstein–Barr virus DNA test*
 Negative95 (38.0%)90 (34.6%)
 ∼4,000 copies per mL97 (38.8%)99 (38.1%)
 >4,000 copies per mL54 (21.6%)69 (26.5%)
 Missing4 (1.6%)2 (0.8%)
DNA (copies per mL), median (IQR)287 (0–3068)349 (0–4463)
  • Note: Data are n (%) or median (range), unless otherwise stated. *The plasma Epstein–Barr virus DNA test was optional in this trial and was not done for all enrolled patients.